Abstract Details

Title Botulinum Toxin Type A Treatment of Disabling Migraine Headaches: A Randomized, Double-Blind, Placebo-Controlled Study

Topic

Presentation(s)

Poster/Presentation
Number 005

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Fidel Meira, MD (Hospital Madre Teresa)	No disclosure on file
	No disclosure on file
Shabnam Pakneshan, MD (henry Ford Medical group)	No disclosure on file
Evanthia Bernitsas, MD, FAAN (Wayne State School of Medicine)	Dr. Bernitsas has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Bernitsas has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Vanda. The institution of Dr. Bernitsas has received research support from Roche/Genentech.

��ɫ��